Pegloticase
- Generic Name
- Pegloticase
- Brand Names
- Krystexxa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 885051-90-1
- Unique Ingredient Identifier
- R581OT55EA
- Background
Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. In gout patients treated with pegloticase, the conversion of uric acid to allantoin leads to...
- Indication
Pegloticase is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
- Associated Conditions
- Chronic, refractory Gout
- Associated Therapies
- -
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06229145
- Locations
- 🇺🇸
Altoona Center for Clinical Research - Research, Duncansville, Pennsylvania, United States
🇺🇸The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Orthopedic Physicians Alaska - Rheumatology and Infusion, Anchorage, Alaska, United States
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT04762498
- Locations
- 🇺🇸
ProHealth Research Center, Doral, Florida, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸Napa Research Center, Pompano Beach, Florida, United States
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04745910
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01739660
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00080210
- Locations
- 🇺🇸
University of Chicago Dept of Medicine, Chicago, Illinois, United States
🇺🇸North Shore University Hospital Division of Rheumatology, Manhasset, New York, United States
🇺🇸Oregon Health & Science University Arthritis & Rheumatic Diseases, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.